PERSPECTIVE THERAPEUTICS, INC.
Last · —$2.24-0.03 (-1.32%)live · yahoo · 1h ago
Market cap$255.70M—
P/E · TTM—fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-16
- Operating Cf Burn
- Cash Runway Low
- Accumulated Deficit High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Cash Runway Low — Cash runway ~0.4 years
- Accumulated Deficit High — Accumulated deficit / equity 162%
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.25
Est. revenue
51,790
Press & signals
- GlobeNewswire
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
- GlobeNewswire
Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium
- GlobeNewswire
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags